The role of pharmacogenomics in Advancing Personalised Medicine: Implications for Drug Efficacy Safety and clinical practice Integration

This study explores the role of pharmacogenomics in advancing personalized medicine, with a focus on improving drug efficacy, minimizing adverse drug reactions (ADRs), and integrating genomic data into clinical decision-making. As personalized medicine continues to evolve, pharmacogenomics offers a transformative approach by tailoring drug therapy based on individual genetic profiles. The study employed a quantitative, experimental research design, targeting 159 clinical pharmacologists and medical practitioners from Punjab, Pakistan. Participants were selected through purposive sampling, and data were collected using structured questionnaires assessing knowledge, application, and outcomes related to pharmacogenomic testing. Statistical analyses included chi-square tests to evaluate the impact on ADRs and efficacy, logistic regression to examine the correlation between specific gene variants (CYP2D6, CYP2C9, CYP2C19) and drug response, and ANOVA to assess the effectiveness of integrating pharmacogenomic guidelines into clinical practice. Results revealed a statistically significant improvement in treatment outcomes and reduced ADRs among patients who received genotype-guided therapy. Furthermore, strong associations were identified between genetic variants and medication responses, validating the predictive value of pharmacogenomic data. The study concludes that with proper integration, pharmacogenomics can play a vital role in optimizing patient care and promoting safer, more effective treatment strategies.